2213 completed, 625 recruiting, 541 unknown, 423 terminated. 1345 Not applicable, 1287 Phase 2, 662 Phase 1, 427 Phase 3, 86 Phase 4.
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria (a) Training and (b) Supported risk assessment - Prostate Cancer, Risk Assessment | Not applicable | Not yet recruiting | Ahmadu Bello University | 89 | 2029-03-01 | 2026-07-29 |
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans Survey - Head and Neck Cancer, Prostate Cancer | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 94 | 2027-03-01 | 2026-10-01 |
| Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA) Radio-induced Lymphocyte Apoptosis (RILA) Assay, Stereotactic body radiotherapy (SBRT) - Prostate Cancer | Not applicable | Not yet recruiting | Clinique Sainte Clotilde | 220 | 2027-02-01 | 2026-10-26 |
| iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer Interviews - Prostate Cancer | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-01-31 | 2026-10-06 |
| HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer Clomiphene Citrate 25mg - Prostate Cancer | Phase 2 | Not yet recruiting | University of Nebraska | 83 | 2027-01-31 | 2026-10-20 |
| Quality and Safety of Real-Time Brachytherapy Treatments: Clinical Implementation of a Multipoint Scintillation Detector for Treatment Monitoring Brachytherapy treatment monitoring using a plastic scintillation detector - Prostate Cancer, Gynecologic Cancers | Not applicable | Not yet recruiting | CISSS de Chaudière-Appalaches | 25 | 2027-01-15 | 2026-10-21 |
| Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening Veteran Peer Decision Coaching Session for PSA Screening - Prostate Cancer | Not applicable | Not yet recruiting | VA Office of Research and Development | 228 | 2027-01-04 | 2026-10-21 |
| ALSO-PERFORM Study. ALternating Stereotaxic Or PElvic Radiotherapy FOR Metachronic Metastatic Prostate Cancer Prostate Cancer | Not yet recruiting | Amsterdam UMC, location VUmc | 130 | 2027-01-01 | 2026-10-08 | |
| Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer weekly CT or MR online adaptive definitive SBRT - Prostate Cancer | Not applicable | Not yet recruiting | University of Zurich | 54 | 2027-01-01 | 2026-08-21 |
| Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients Tamoxifen - Hypogonadism, Prostate Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 96 | 2026-12-31 | 2026-10-22 |
| Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer Prostate-Targeted PET- Scan (P-PET). - Prostate Cancer | Not applicable | Not yet recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 25 | 2026-12-30 | 2026-09-25 |
| Whole Versus Partial Gland Boost During Prostate SBRT Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Not yet recruiting | University of Nebraska | 160 | 2026-12-25 | 2026-11-03 |
| Training on Systemic and Organ Spec. PM in PC Exercise - Prostate Cancer | Not applicable | Not yet recruiting | Massachusetts General Hospital | 20 | 2026-12-10 | 2026-08-17 |
| Prostate Cancer in UK Prisons: A Retrospective Data Analysis Prostate Cancer | Not yet recruiting | Royal Marsden NHS Foundation Trust | 9007 | 2026-12-03 | 2026-10-16 | |
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer Hospital based follow up, Primary care based follow up, Planned shared care follow up - Prostate Cancer | Not yet recruiting | Imperial College London | 100000 | 2026-12-01 | 2026-10-06 | |
| Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle Daily Adaptive MR-Enhanced SBRT with Neurovascular Bundle Sparing - Prostate Cancer, Localized Prostate Carcinoma | Not applicable | Not yet recruiting | University of Zurich | 48 | 2026-12-01 | 2026-11-04 |
| PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer Prostate Only Radiation Therapy (PORT), Prostate + Whole Pelvis Radiation Therapy (P-WPRT) - Prostate Cancer | Phase 2 | Not yet recruiting | AHS Cancer Control Alberta | 250 | 2026-12-01 | 2026-11-04 |
| POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions PET Imaging with Flotufolastat F 18 - Prostate Cancer, PI-RADS 3 Prostate Lesion | Not applicable | Not yet recruiting | SimonMed Imaging | 130 | 2026-12-01 | 2026-11-04 |
Showing 20 of 4524. Sign in to see all of them.
Prostatic Neoplasms (4524) · Breast Neoplasms (351) · Neoplasms (257) · Lung Neoplasms (176) · Colorectal Neoplasms (159) · Neoplasm Metastasis (147) · Ovarian Neoplasms (138) · Urinary Bladder Neoplasms (109) · Pancreatic Neoplasms (104) · Carcinoma, Non-Small-Cell Lung (100) · Head and Neck Neoplasms (87) · Kidney Neoplasms (86) · Colonic Neoplasms (82) · Melanoma (67) · Esophageal Neoplasms (65)
Genital Diseases (4521) · Urogenital Diseases (4521) · Genital Diseases, Male (4517) · Male Urogenital Diseases (4515) · Neoplasms by Site (4514) · Genital Neoplasms, Male (4511) · Urogenital Neoplasms (4501) · Prostatic Diseases (4495) · Neoplasms (4267) · Pathological Conditions, Signs and Symptoms (489) · Skin and Connective Tissue Diseases (387) · Skin Diseases (383) · Breast Diseases (364) · Female Urogenital Diseases (347) · Female Urogenital Diseases and Pregnancy Complications (347)
Docetaxel (187) · Prednisone (143) · Leuprolide (136) · Radiotherapy (134) · Goserelin (104) · bicalutamide (104) · enzalutamide (103) · Abiraterone Acetate (86) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (83) · Androgen Antagonists (77) · Radiosurgery (67) · Magnetic Resonance Spectroscopy (59) · Surveys and Questionnaires (59) · Gonadotropin-Releasing Hormone (49) · gallium 68 PSMA-11 (49)
Memorial Sloan Kettering Cancer Center (128) · National Cancer Institute (NCI) (90) · M.D. Anderson Cancer Center (83) · University Health Network, Toronto (61) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (57) · Dana-Farber Cancer Institute (54) · University of California, San Francisco (46) · Ferring Pharmaceuticals (41) · Duke University (40) · AstraZeneca (37) · Weill Medical College of Cornell University (36) · Chinese University of Hong Kong (33) · Case Comprehensive Cancer Center (32) · University of Wisconsin, Madison (32) · NYU Langone Health (31)
United States (2326) · Canada (451) · France (291) · United Kingdom (290) · China (259) · Italy (189) · Germany (182) · Netherlands (166) · Spain (140) · Belgium (132) · Australia (125) · South Korea (94) · Denmark (87) · Switzerland (85) · Sweden (77)
Mary-Ellen Taplin, MD (14) · Rahul Aggarwal, MD (13) · Chi Fai NG, MD (12) · Michael Morris, MD (12) · Peter A Pinto, M.D. (9) · James Eastham, MD (8)
PMID 34350976, PMID 33270906, PMID 33465252, PMID 24722180, PMID 25712310, PMID 25819287, PMID 36884035, PMID 38320143, PMID 38421252, PMID 22747660, PMID 25592642, PMID 27626136, PMID 32994091, PMID 24423462, PMID 25614256, PMID 25754526, PMID 26512712, PMID 27626365, PMID 29272162, PMID 36383907, PMID 36596347, PMID 37070660, PMID 38421243, PMID 40645505, PMID 41698328, PMID 17182834, PMID 18212313, PMID 19637244, PMID 20122025, PMID 20818327, PMID 20964826, PMID 21149658, PMID 21751904, PMID 21917607, PMID 22056152, PMID 22547274, PMID 22958524, PMID 23000088, PMID 23158413, PMID 23228299, PMID 23411385, PMID 24072344, PMID 24101042, PMID 24207135, PMID 24297031, PMID 24412228, PMID 24590644, PMID 24881730, PMID 24957547, PMID 24974051
2017 (16), 2023 (16), P30CA072720 (13), U10CA031946 (13), 2016 (12), P30CA022453 (11), 2019 (10), P30CA043703 (10), 2008 (9), 2025 (9), 2014 (8), P30CA008748 (8), P30CA016672 (8), 2009 (7), P30CA012197 (7)